3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
19
Terminated
7
Active not recruiting
5
Recruiting
4
Withdrawn
3
Unknown
2
Available
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
21
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Neoplasm, Residual
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
27
Rituximab
20
Etoposide
14
Cytarabine
13
Melphalan
11
Vincristine
10
fludarabine
9
Prednisone
9
Doxorubicin
9
Busulfan
8
Peripheral Blood Stem Cell Transplantation
7
Radiotherapy
6
Filgrastim
6
Cyclosporine
6
Bendamustine Hydrochloride
6
fludarabine phosphate
5
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
5
Mycophenolic Acid
5
Cisplatin
5
tositumomab I-131
4
ibritumomab tiuxetan
4
Ifosfamide
4
Dexamethasone
4
Carmustine
4
relmacabtagene autoleucel
3
Thiotepa
3
Indium
3
Immunotherapy, Adoptive
3
Gemcitabine
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, Non-Hodgkin
×
venetoclax
×
Clear all
NCT05005299
2023-08-01
VICTORY
Melbourne Health
Phase 1
Unknown
18 enrolled
NCT03505944
2021-10-13
VALERIA
Nordic Lymphoma Group
Phase 1/2
Unknown
59 enrolled